27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics.
BioBridge Ltd, the UK-based bioscience innovation consultancy, announces the start of a new working relationship with Osprey Consultants LLC, a US-based animal health consultancy specialising in veterinary medicine product development and commercialisation. BioBridge and Osprey will assist each other in providing services for their respective clients.
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.
Collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline
Cambridge, UK, 25 June, 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announced they have signed a neurodegeneration drug discovery collaboration agreement. Combining the two companies’ technology platforms to validate novel targets, the initial focus will be on Parkinson’s disease.
With two acquisitions complete this year, Entrust Resource Solutions are now creating new jobs across the UK by adding a specialist Resourcing Team to their business.
Entrust Resource Solutions recently announced an ambitious growth and acquisition strategy. This started with the addition of two resourcing consultancies to their portfolio, with Horton International (UK) and SCI Search and Selection joining Entrust People. To keep up with their rate of growth and better support their team, the business is now creating a new Resourcing Team.
ScreenIn3D, a partner of AMSBIO, has received a share of the £1 million plus prize pot and will receive ongoing support from partners of Scottish Edge - a respected regional business support agency.
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines
Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms
Reading Scientific Services Ltd (RSSL) is tripling the size of its pharmaceutical microbiology laboratory with the opening of a new, state-of-the-art facility in Wokingham. The move follows sustained market demand for the consultancy’s microbiological analysis services. It not only provides the operational space to significantly increase capacity, but also signals a commitment to the future expansion of test methods and staff levels.
Psychiatry Consortium to address unmet patient needs
Today (18th June 2019) Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK announce an innovative drug discovery consortium with industry, supported by the Wellcome Trust.
The Consortium will focus on the identification and validation of novel drug targets for psychiatric diseases, including the psychiatric symptoms associated with dementia.